Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
3
×
boston blog main
boston top stories
3
×
clinical trials
life sciences
national blog main
3
×
dyne therapeutics
fda
myotonic dystrophy type 1
national top stories
rare disease drugs
san diego blog main
san francisco blog main
astellas pharma
atlas venture
audentes therapeutics
avapritinib
avidity biosciences
biotech ipos
bluebird bio
blueprint medicines
cstone pharmaceuticals
deals
duchenne muscular dystrophy
eli lilly
european medicines agency
facioscapulohumeral muscular dystrophy
fisogatinib
flatiron health
gene therapy
genentech
hepatocellular carcinoma
investing
jeff albers
joshua brumm
kaleido biosciences
medullary thyroid cancer
metacrine
muscular dystrophy
What
drug
medicines
muscle
3
×
dyne
genetic
ipo
rare
therapeutics
ago
approval
biotechs
blueprint
brings
cancer
candidate
company
considering
currently
data
developing
diseases
disorders
dyne’s
early
expected
experimental
eyes
fda
having
humans
ipos
long
marketing
million
muscular
pact
preclinical
raised
reach
regulatory
Language
unset
Current search:
muscle
×
boston
×
" national blog main "
×
" boston top stories "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact